NCT04166825|Recruiting
Ovarian Hyperstimulation and Fibrin Clot Properties.
The Impact of Different Ovarian Hyperstimulation Protocols on Coagulation and Fibrinolysis.
Loading search results
The Impact of Different Ovarian Hyperstimulation Protocols on Coagulation and Fibrinolysis.
Sponsor study identifier
interventional
300
1 country
1
Study Start
November 18, 2019
Actual (reported)Primary Completion
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women. Comparative analysis between different ovarian stimulation protocols on thrombin formation and efficiency of fibrinolysis in women diagnosed with infertility.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 13, 2019
Actual (reported)November 18, 2019
Actual (reported)November 18, 2019
Actual (reported)January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Fibrin clot properties before and after the ovarian hyperstimulation.
Coagulation (endogenous thrombin potential) and fibrinolysis (F1+2, clot lysis time)parameters assessment.
4 months
Endometriosis and fibrin clot properties.
1 cycle
Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
Assessment of thrombin generation and efficiency of fibrinolysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Department of Gynecological Endocrinology Jagiellonian University Medical College
Krakow, Małopolska, 30-501, Poland
Pirog M, Jach R, Zabczyk M, Natorska J. Unfavorably altered fibrin clot properties in women with unexplained infertility: association with pregnancy outcomes. Arch Gynecol Obstet. 2026 Apr 27;313(1):173. doi: 10.1007/s00404-026-08418-y.
Pirog M, Kacalska-Janssen O, Jach R, Wyroba J, Chrostowski B, Zabczyk M, Natorska J. GnRH Antagonist Protocol Enhances Coagulation During Controlled Ovarian Stimulation for IVF. Reprod Sci. 2022 Dec;29(12):3521-3531. doi: 10.1007/s43032-022-01026-6. Epub 2022 Jul 12.
First Submitted
November 13, 2019
First Posted
November 18, 2019
Study Start
November 18, 2019
Actual (reported)Primary Completion
January 2026
Estimated (date passed)Autologous Ovarian Tissue Transplantation
Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 5, 2025
Record last verified: 2025-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: